Showing 1671-1680 of 2657 results for "".
- Glaucoma Research Foundation to Recognize Santen Pharmaceutical at Annual Gala in San Franciscohttps://modernod.com/news/glaucoma-research-foundation-to-recognize-santen-pharmaceutical-at-annual-gala-in-san-francisco/2481369/Santen Pharmaceutical will receive the Glaucoma Research Foundation's Catalyst Award at the Glaucoma 360 Annual Gala on February 2, 2023, in San Francisco, the foundation's President and CEO Thomas M. Brunner announced. Santen is being recognized for th
- Dr. Reddy's Launches Generic Version of Durezol in the UShttps://modernod.com/news/dr-reddys-launches-generic-version-of-durezol-in-the-us/2481368/Following FDA approval, Dr. Reddy’s Laboratories announced the US launch of "Dr. Reddy’s Difluprednate Ophthalmic Emulsion 0.05%," a therapeutic generic equivalent to Durezol (Difluprednate Ophthalmic Emulsion 0.05%; Novartis), according to a company news release.
- Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCEDhttps://modernod.com/news/kala-pharmaceuticals-announces-fda-acceptance-of-ind-application-for-kpi-012-for-the-treatment-of-pced/2481312/Kala Pharmaceuticals announced that the FDA has accepted an investigational new drug (IND) application for the company’s lead product candidate, KPI-012, a human mesenchymal stem cell secretome (MSC-S), initially in development for the treatment of persistent corneal epithelial de
- Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi for In-Office Pupil Dilationhttps://modernod.com/news/eyenovia-announces-fda-acceptance-of-new-drug-application-for-mydcombi-for-in-office-pupil-dilation/2481289/Eyenovia announced that the FDA has accepted for review the company’s new drug application (NDA) for MydCombi ophthalmic spray. MydCombi is a drug-device combination product that comprises the company’s proprietary, first-in-class combination of tropicamide and phe
- Alcon Completes Acquisition of Aerie Pharmaceuticalshttps://modernod.com/news/alcon-completes-acquisition-of-aerie-pharmaceuticals/2481258/Alcon announced that it has completed its acquisition of Aerie Pharmaceuticals. In August, Alcon announced its was acquiring Aerie for about $770 million, or $15.25 per share—a premium of 37% to Aerie’s closing price prior to the deal. The deal bolsters Alcon's
- Replay Launches Its First HSV Gene Therapy Company, Eudora, Focused on Retinal Eye Diseasehttps://modernod.com/news/replay-launches-its-first-hsv-gene-therapy-company-eudora-focused-on-retinal-eye-disease/2481216/Replay announced the launch of Eudora, an HSV gene therapy company targeting genetic retinal diseases. It is the first of Replay’s product companies to leverage its high payload capacity herpes simplex virus (HSV) delivery vector, synHSV. Eudora’s co-founders, Professors Joe Glor
- Heru Makes Appointments to Its Executive Leadership Teamhttps://modernod.com/news/heru-makes-appointments-to-its-executive-leadership-team/2481210/Heru announced several key executive appointments across its leadership team and board of directors designed to strengthen the company’s commercial operation and support its next phase of growth. Fred Drasner has been appointed as Heru’s Chairman of the Board of
- NEI's Anterior Segment Initiative has Funded Eight Research Projectshttps://modernod.com/news/neis-anterior-segment-initiative-has-funded-eight-research-projects/2481195/The National Eye Institute's Anterior Segment Initiative has funded eight research projects to explore the innervation of the eye’s surface. The collaborative projects will examine the molecular, morphological, and functional aspects of corneal pain and sensation, and tearing reflexes.
- Eyenuk Secures $26 Million Series A Funding to Accelerate Global Access to AI-Powered Eye-Screening Technologyhttps://modernod.com/news/eyenuk-secures-26-million-series-a-funding-to-accelerate-global-access-to-ai-powered-eye-screening-technology/2481183/Eyenuk announced it has secured $26 million in a Series A financing round, bringing the company’s total funding to over $43 million. The capital raise was led by AXA IM Alts and was joined by new and existing investors including T&W Medical A/S, A&C Foelsgaard Alternativer ApS,
- Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 US and European Patentshttps://modernod.com/news/azura-ophthalmics-expands-broad-intellectual-property-portfolio-to-12-us-and-european-patents/2481182/Azura Ophthalmics announced the company’s US 11,459,351 patent (the ‘351 patent) was granted by the US Patent and Trademark Office. This patent strengthens the company’s extensive portfolio protecting its use of dual-action keratolytic drug conjugates in developme